Who
Kathryn Romano
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Krystal Biotech.
In numbers
- Trades disclosed
- 142
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $16.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Jan 2020
- Last trade
- 2 Mar 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $201K750 at $267.60 | filing |
| 2 Mar 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $201K750 at $267.60 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code F | $899K3,262 at $275.64 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code M | —550 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —550 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,575 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,442 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code F | $66K240 at $275.64 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —550 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,575 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code F | $899K3,262 at $275.64 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code M | —550 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code F | $66K240 at $275.64 | filing |
| 27 Feb 2026filed 3 Mar 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,442 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code M | $794K12,500 at $63.55 | filing |
| 9 Feb 2026filed 11 Feb 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
News
Monte Rosa Therapeutics (NASDAQ:GLUE) versus Krystal Biotech (NASDAQ:KRYS) Head to Head SurveyKRYS · tickerreport.com · 21 Oct 2026Krystal Biotech Sees Broad Antitumor Activity With KB113 In Gorlin Syndrome; Stock UpKRYS · rttnews.com · 15 Oct 2026Krystal Biotech Reports Over 80% Lesion Regression With KB113 In Gorlin SyndromeKRYS · rttnews.com · 15 Oct 2026
0 headlines in the last 90 days name Kathryn Romano; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.